News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Assenagon Asset Management S.A. significantly reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 82% in Q2 2026, selling over 400,000 shares but still retaining a position worth approximately $5 million. Despite mixed analyst ratings, institutional investors hold a substantial portion of the company. TG …
The US market has performed flat recently but is up 19% over the past year, with earnings projected to grow 17% annually. This article identifies high-growth tech stocks by focusing on companies with strong innovation and financial health, presenting three top picks: TG Therapeutics …
Despite a significant Q2 earnings per share miss, TG Therapeutics (TGTX) saw its stock slip by 5%, but retail investors remain bullish due to CEO Michael Weiss's optimistic outlook for its MS drug, Briumvi. The company raised its 2026 total global revenue target to …
First Trust Advisors LP significantly reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 43.6% in the first quarter, selling 38,545 shares and retaining 49,947 shares valued at $1.66 million. Despite institutional ownership of 58.58%, the biopharmaceutical company reported mixed financial results, with revenue exceeding …
TG Therapeutics reported strong Q2 2026 financial results, with U.S. BRIUMVI revenue reaching $227.7 million, a 64% increase year-over-year. The company raised its full-year U.S. revenue guidance to $890-$905 million, driven by record patient starts and expanded physician adoption. TG Therapeutics is also making …
Argus has raised its target price for TG Therapeutics, Inc. (TGTX) to $60.00, noting the company's focus on novel treatments for B-cell diseases. The biopharmaceutical company is described as fully integrated and commercial-stage. The current stock price for TGTX is $49.76.
TG Therapeutics (NASDAQ:TGTX) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $63.00. The company recently reported a 70.2% year-over-year revenue increase to $240.34 million, surpassing estimates, though adjusted EPS of $0.05 missed the $0.31 consensus. Institutional …
TG Therapeutics director Laurence N. Charney gifted a total of 6,050 shares of common stock to a 501(c)(3) institution on August 6-7, 2026. The shares were transferred at $0.00 per share, and Charney retains no beneficial ownership or pecuniary interest in the gifted stock. …
TG Therapeutics reported a 7.4% stock drop following a Q2 2026 profit decline, despite increasing its full-year 2026 global revenue guidance to US$950 million. The company's investment narrative relies heavily on the continued success of BRIUMVI and its upcoming subcutaneous version, which is expected …
This article lists various ETFs that invest in TG Therapeutics, Inc. stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each fund. The ETFs primarily …
TG Therapeutics reported its 2026 quarterly results with revenue of $240.34 million, an increase from $141.15 million in the prior year, and diluted EPS of $0.05, down from $0.17. The net income for the quarter was $7.78 million, compared to $28.19 million in the …
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for the first half of 2026, with total revenue reaching $445.3 million, primarily driven by BRIUMVI sales for multiple sclerosis both in the U.S. and internationally. The company achieved profitability, posting a net income of $27.6 …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results, with revenue of US$240.34 million and earnings of US$0.05 per share, …
H.C. Wainwright has increased its price target for TG Therapeutics (NASDAQ:TGTX) to $78 from $77, maintaining a Buy rating after the company's strong second-quarter 2026 earnings report. The firm noted Briumvi's US revenue exceeded estimates and its market share grew, leading TG Therapeutics to …
TG Therapeutics (TGTX) stock is currently viewed as undervalued, despite a significant 3-year return. The company's P/E ratio is lower than both the biotech industry average and its peers, suggesting a discount relative to its fundamentals. While strong revenue growth from BRIUMVI is positive, …
TG Therapeutics announced strong second-quarter 2026 financial results, with total global revenue reaching approximately $240 million and U.S. BRIUMVI® net product revenue at $228 million. The company has raised its full-year 2026 revenue guidance for both total global revenue to $950 million and U.S. …
TG Therapeutics (TGTX) reported a Q2 2026 revenue increase but missed EPS estimates, leading to a 15.9% stock drop. Despite this, the company raised its 2026 global revenue outlook to about US$950 million, driven by confidence in Briumvi's momentum and its broader pipeline. Investors …
TG Therapeutics (TGTX) stock dropped 11% after earnings, despite strong revenue growth from its multiple sclerosis drug, BRIUMVI. The company's profit shrank significantly due to heavy manufacturing-related charges, raising concerns about margin pressure and reliance on BRIUMVI. This performance has fueled arguments from bears …
TG Therapeutics (TGTX) reported mixed Q2 2026 financial results, with total global revenue exceeding consensus estimates but non-GAAP earnings per share significantly missing expectations. The company also raised its full-year guidance, though it still fell slightly below analyst projections, leading to a negative reaction …
Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports. Continue Reading
[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * TG Therapeutics is down ~11% in Monday trading after reporting Q2 EPS that missed expectations. * Diluted EPS of $0.05 compares to $0.17 in the year-ago period. * Although TG was helped in …
TG Therapeutics TGTX reported earnings of 5 cents per share for the second quarter of 2026, missing the Zacks Consensus Estimate of 41 cents. The company had reported earnings of 17 cents per share in the year-ago quarter. Total revenues in the second quarter …
Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports. Continue Reading
TG Therapeutics (TGTX) reported $240.34 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 70.3%. EPS of $0.05 for the same period compares to $0.17 a year ago. The reported revenue represents a surprise of +4.08% over the Zacks …
TG Therapeutics, Inc. (NASDAQ: TGTX) generated $616.29 million USD in revenue last year. The primary source of this revenue, $616.29 million USD, came from its "Novel Treatments for B-cell Diseases" segment, an increase from $329.00 million USD the previous year. All reported revenue originated …
TG Therapeutics has raised its full-year 2026 revenue guidance, projecting that its multiple sclerosis drug, Briumvi, is on track to achieve an annualized U.S. revenue run rate of approximately $1 billion. This update follows a strong Q2 performance where global revenue increased by 70%, …
This article analyzes Tg Therapeutics Inc. (TGTX) and its impact on rotational strategy timing, highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis …
* TG Therapeutics (TGTX [https://seekingalpha.com/symbol/TGTX]) is scheduled to announce Q2 earnings results on Monday, August 3rd, before market open. * The consensus EPS Estimate is $0.44 [https://seekingalpha.com/symbol/TGTX/earnings/estimates] and the consensus Revenue Estimate is $229.79M (+62.8% Y/Y). * Over the last 3 months, EPS estimates …
Search by ticker symbol or company name and select a result to open its chart.